OBSERVATIONAL STUDY OF TREATMENT OF EPIDERMAL GROWTH FACTOR RECEPTOR ACTIVATING MUTATION POSITIVE (EGFRM plus ) ADVANCED OR RECURRENT NON-SMALL-CELL LUNG CANCER (NSCLC), AFTER RADIOLOGICAL PROGRESSION TO THE FIRST-LINE THERAPY WITH EGFR TYROSINE KINASE INHIBITORS (EGFR-TKI)

被引：0
|
作者：
Kunitoh, Hideo [1 ]
Tanai, Chiharu [2 ]
Hosomi, Yukio [3 ]
Yoh, Kiyotaka [4 ]
Goto, Yasushi [5 ]
Ohashi, Yasuo [6 ]
机构：
[1] Mitsui Mem Hosp, Tokyo, Japan
[2] Ntt Med Ctr, Div Respirol, Tokyo, Japan
[3] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[4] Natl Canc Ctr Hosp East, Div Thorac Oncol, Kashiwa, Chiba, Japan
[5] Tokyo Univ Hosp, Dept Resp Med, Tokyo, Japan
[6] Univ Tokyo, Dept Biostat, Tokyo 1138654, Japan
来源：
JOURNAL OF THORACIC ONCOLOGY | 2013年 / 8卷
关键词：
EGFR; progression; RECIST; beyond PD;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P1.11-011
引用
收藏
页码：S597 / S598
页数：2
相关论文
共 50 条
  • [41] EGFR inhibitors as the first-line systemic treatment for advanced non-small-cell lung cancer
    Kao, Hsiang-Fong
    Lin, Chia-Chi
    Yang, James Chih-Hsin
    FUTURE ONCOLOGY, 2013, 9 (07) : 991 - 1003
  • [42] PROGRESSION-FREE SURVIVAL IS A POOR SURROGATE ENDPOINT FOR OVERALL SURVIVAL IN THE FIRST LINE EGFR-TKI TREATMENT IN ADVANCED NON-SMALL-CELL LUNG CANCER WITH EGFR MUTATION
    Liao, Ri-Qiang
    Yang, Xue-Ning
    Yan, Hong-Hong
    Zhou, Qing
    Wu, Yi-Long
    Zhong, Wen Zhao
    JOURNAL OF THORACIC ONCOLOGY, 2013, 8 : S615 - S615
  • [43] Epidermal growth factor receptor (EGFR) mutation testing and first-line treatment with gefitinib as a strategy in the treatment of patients with advanced non-small cell lung cancer (NSCLC).
    Lopes, G.
    Segel, J.
    Tan, D. S. W.
    Do, Y.
    Mok, T.
    Finkelstein, E.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [44] Real world data on epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKI) use in advanced/metastatic non-small cell lung cancer (NSCLC) with EGFR mutations in Singapore
    Chua, B.
    Tan, E. H.
    Lim, D. W-T.
    Ang, M-K.
    Tan, D. S. W.
    Ng, Q-S.
    Kanesvaran, R.
    Jain, A.
    Tan, W-L.
    Toh, C. K.
    Rajasekaran, T.
    ANNALS OF ONCOLOGY, 2018, 29
  • [45] First-generation epidermal growth factor receptor tyrosine kinase inhibitors in EGFR mutation - Positive non-small cell lung cancer patients
    Sequist, Lecia V.
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (06) : S143 - S145
  • [46] Clinical outcome of bevacizumab or ramucirumab combined with epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors as the first line therapy in susceptible EGFR-mutated advanced non-small-cell lung
    Kuo, Chia-Yu
    Tsai, Ming-Ju
    Hung, Jen-Yu
    Lee, Mei-Hsuan
    Wu, Kuan-Li
    Tsai, Yu-Chen
    Chuang, Cheng-Hao
    Huang, Chung-Wen
    Chen, Chin-Ling
    Yang, Chih-Jen
    Chong, Inn-Wen
    KAOHSIUNG JOURNAL OF MEDICAL SCIENCES, 2024, 40 (05): : 467 - 476
  • [47] First-line tyrosine kinase inhibitors in EGFR mutation-positive non-small-cell lung cancer: a network meta-analysis
    Holleman, Marscha S.
    van Tinteren, Harm
    Groen, Harry J. M.
    Al, Maiwenn J.
    Uyl-de Groot, Carin A.
    ONCOTARGETS AND THERAPY, 2019, 12 : 1413 - 1421
  • [48] Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)
    Gelatti, Ana C. Z.
    Drilon, Alexander
    Santini, Fernando C.
    LUNG CANCER, 2019, 137 : 113 - 122
  • [49] American Society of Clinical Oncology Provisional Clinical Opinion: Epidermal Growth Factor Receptor (EGFR) Mutation Testing for Patients With Advanced Non-Small-Cell Lung Cancer Considering First-Line EGFR Tyrosine Kinase Inhibitor Therapy
    Keedy, Vicki Leigh
    Temin, Sarah
    Somerfield, Mark R.
    Beasley, Mary Beth
    Johnson, David H.
    McShane, Lisa M.
    Milton, Daniel T.
    Strawn, John R.
    Wakelee, Heather A.
    Giaccone, Giuseppe
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15) : 2121 - 2127
  • [50] Small Molecule Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors in Non Small Cell Lung Cancer Treatment
    Schettino, Clorinda
    Bareschino, Maria Anna
    Maione, Paolo
    Rossi, Antonio
    Ciardiello, Fortunato
    Gridelli, Cesare
    CURRENT CANCER THERAPY REVIEWS, 2007, 3 (04) : 226 - 235
12345